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Abstract
The most precise evaluation of thyroid masses is by high-sensitive ultrasound. 
Complementary to B-mode ultrasound, elastography can add valuable information 
by determining tissue stiffness—an important predictor for malignancy. All major 
guidelines recommend nodules with high suspicious ultrasound characteristics 
larger than 1 cm to be addressed to ultrasound-guided fine needle aspiration 
biopsy (FNAB) to rule out malignancy. The main limitation of this procedure is 
represented by indeterminate cytology, which accounts for up to 20–25% of biopsy 
results. Molecular markers imply elevated costs and their performance needs 
further study. Elastography may be helpful in establishing the optimal therapeutic 
attitude for this cytological category. Currently, there are two ultrasound elastogra-
phy methods available for assessing tissue stiffness using the parallel deformation 
to the applied force direction (strain) or the perpendicular deformation to the force 
direction (shear wave). These methods will be presented and compared in this 
chapter, with their indications and limitations for a better understanding of their 
application in nodular thyroid pathology.
Keywords: thyroid cancer, ultrasound, elastography, strain, shear wave,  
malignancy risk assessment
1. Introduction
Thyroid cancer incidence increased in the last three decades by up to 211%, not 
only as a result of a better ability to detect very small lesions, by means of high-
resolution ultrasonography, but also secondary to a real increase of thyroid cancer 
incidence, regardless of size, gender, or age groups [1, 2]. Even in these conditions, 
the prevalence of thyroid cancer, in the entire group of thyroid nodules, reaches a 
percentage of 15% [3], the main challenge for clinicians being the correct identifica-
tion of which nodules to refer to fine needle aspiration cytology (FNAC) or directly 
to surgery, and which to follow by means of ultrasound evaluation [2, 4].
“A thyroid nodule is defined as a discrete lesion within the thyroid gland that is 
ultrasonographically distinct from the surrounding thyroid parenchyma” [4]. Nodules 
are usually noticed either by the patient when causing clinical disturbances or compres-
sive symptoms, or by the clinician when performing a thyroid screening or a radiologic 
procedure such as carotid ultrasound or computed tomography of the neck [5].
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When evaluating a thyroid nodule, first line step is represented by running labo-
ratory tests (thyroid-stimulating hormone and thyroid hormones) and performing 
ultrasound evaluation of the gland. Evaluation goals include identification of the 
small percentage of malignant nodules, of those that impair thyroid function and of 
compressive symptoms (dysphonia and dyspnea) [6, 7].
Personal or family history of thyroid cancer, significant exposure to radiations, 
increases the malignancy risk of the nodule and should be screened for [8].
It is desired to have uniform and standardized reports, given the increased 
accessibility of the ultrasound equipment and considerable number of clinicians 
that perform this type of evaluation. Reports will always record nodule position, 
number, extracapsular relations, and the following features of the lesions: size, 
shape, margins, echogenicity, echo texture, internal composition (solid, cystic, or 
mixed), presence of calcifications, and vascular pattern [2].
There are some US features described that are considered highly specific for 
malignancy, as the presence of microcalcifications, rim calcifications, infiltrative 
margins, extrathyroidal extension, mostly solid composition, marked hypoechoic 
texture, and “taller than wide” shape, respectively, the vertical diameter bigger 
than the transverse diameter. Spongiform appearance, smooth margins, and cystic 
composition are associated with benignity [6].
Vascularization assessment is considered to have poor interobserver agreement 
and it has highly dependent on the US equipment used [9].
Additionally, abnormal cervical lymph nodes should be assessed, especially in 
patients with intermediate- and high-risk thyroid nodules [10].
Various authors and societies proposed risk-stratification systems for thyroid 
nodules on US. They were initially introduced by classifying thyroid nodules which 
displayed any suspicious feature as malignant. Thus, starting with Kim et al. in 
2002, risk-stratification systems were conceived as qualitative grading systems.
Assessment based on a combination of US features has been proposed as a 
better method of risk stratification. The system developed into a quantitative 
scoring system, on which the concept of thyroid imaging reporting and data system 
(TI-RADS) is based. Horvath et al., inspired by the previously existing breast 
imaging reporting and data system (BI-RADS) score, introduced it in 2009. Since 
then, the concept has permanently developed; each new concept proposed having 
its advantages and limitations regarding their practical application [11]. There are 
also data suggesting TI-RADS quantification is better than individual assessment of 
the US characteristics [12].
Different diagnostic qualities are described for each model: Park model: 
Se = 82%, Sp = 65% [13]; Kwak model: Se = 97.4%, Sp = 29.3% [14, 15].
Diagnostic accuracy for Russ’ TI-RADS model was evaluated comparatively 
on gray scale alone and associated with elastography score. When compared to 
cytological results, the study showed Se = 95.7, Sp = 61%, and NPV = 99.7% for gray 
scale only; Se = 98.5%, Sp = 44.7%, and NPV = 99.8% for the combined model using 
gray scale + elastography. For the operated group, these models were also compared 
to pathology results showing Se = 93.2% for gray-scale TI-RADS and Se = 96.7% for 
gray scale + elastography. It was estimated that the number of nodules sent to FNAB 
decreased by 33.8% [9, 10, 16].
Stoian model also calculated strain ratio for each nodule, apart from qualita-
tive SE scoring, with excellent diagnostic value (AUC = 0.95761, 95% confidence 
interval (CI)). In this case, Se = 97.93%, Sp = 86.20%, and NPV = 97.26%. Nodules 
required for FNAB decreased by 43.7% [17].
The 2017 ACR–TIRADS applied on 100 thyroid nodules showed an overall 
Se = 92% and Sp = 44%, with a 29% reduction in the number of nodules that 
require biopsy [18].
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US-guided FNAB represents the next step in thyroid nodule evaluation and 
is considered to be the most accurate and cost-efficient preoperative method for 
identifying malignancy in thyroid nodular lesions, but its indications are broad and 
differ in the guidelines [19, 20]. Complications are rare and are usually represented 
by local pain or minor hematomas, but patients are still sometimes reluctant to 
undergo this procedure [21]. Prior the FNAB, the patients can be questioned for 
the use of blood thinner drugs and hematologic disease such as bleeding-clotting 
disorders.
A category-based reporting system was developed and standardized for thyroid 
FNAB specimens by The Bethesda System for Reporting Thyroid Cytopathology 
(and it has been broadly adopted). Based on this reporting system, thyroid nodule 
cytology can be classified in one of the following six categories: (I) nondiagnostic, 
(II) benign, (III) atypia or follicular lesion of undetermined significance (AUS or 
FLUS), (IV) (suspicion of) follicular neoplasm, (V) suspicious for malignancy, and 
(VI) malignant [22–24].
Each category has its evidence-based recommendation for further clinical 
behavior according to its estimated malignancy risk. The real challenge concerns the 
management of indeterminate cytology lesions (Bethesda categories III–V) [22].
Benign cytology accounts for 60–70% of FNAs, malignant findings for about 
5%—papillary thyroid carcinoma (PTC) being the most common, and indeterminate 
cytology for 10–20% of specimens—atypical modifications, follicular or Hurthle cell 
cancers. The indeterminate category has anywhere from 15 to 60% risk of malig-
nancy, depending on the specifics of the report. Studies recently showed that molecu-
lar markers can help future distinction between benign and malignant nodules in this 
cytological category but there are no recommendations currently in use [20].
The American Association of Clinical Endocrinology 2016 guidelines recom-
mend FNAB for nodules with high US risk if they are ≥10 mm, for intermediate 
US risk nodules ≥20 mm, and low US risk lesions >20 mm that are increasing in 
size or have thyroid cancer history. For nodules between 5 and 10 mm in diameter 
with high-risk US characteristics, they recommend FNAC or watchful waiting. 
Functioning nodules on scintigraphy that lack suspicious US characteristics do not 
have recommendation for FNAC [4].
The American Thyroid Association (ATA) Management Guidelines refer to 
FNAC also for intermediate risk nodules >10 mm [19].
The Korean Thyroid Association (KTA) 2016 Revised Guideline recommends that 
highly suspicious nodules <1 cm should undergo FNAC in order to avoid unnecessary 
long-term follow-up, given that 20–40% of nodules in this category are benign [25].
The number of nodules addressed to FNAC could be reduced, as 60–80% of 
FNACs reveal benign lesions; this low percentage of malignancy detected in the 
nodules sent to FNAC based on US imaging criteria points out the real need for a 
more accurate US diagnostic evaluation [4, 6].
There are some drawbacks regarding FNAC results. About 5% of cases are 
considered qualitative or quantitative insufficient for diagnostic, and Bethesda III 
and IV categories are inconclusive for a final treatment recommendation. In the 
presence of indeterminate cytology, the clinical judgment relies again on patient 
background (clinical risk categories) and ultrasonography aspect [22, 26].
2.  Ultrasound elastography—nodule stiffness as a malignancy  
risk-stratification parameter
US elastography noninvasively evaluates the stiffness of a thyroid nodule by 
measuring the distortion that appears when the nodule is compressed by external 
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pressure (strain elastography) or by assessing the attenuation of the shear waves 
(shear-wave elastography) generated by the transducer [10].
Elasticity is the ability of tissue to resist deformation when an external force 
is applied, or to resume its original shape after the force is removed [27]. Loss of 
elasticity of a tissue on palpation or elastography (“virtual palpation”) gener-
ates suspicion of malignancy. Most solid tumors are mechanically different from 
adjacent tissues, presenting increased stiffness (decreased elasticity) owing to 
desmoplastic transformation—more collagen and myofibroblasts [27, 28].
There are some fibrous benign tumors that can be hard on elastography (histio-
cytofibromas) and some malignant nodules with nonmodified elasticity that can be 
missed by elastography (follicular carcinomas) [28, 29].
The different US elastography techniques that are currently available carry 
various limitations in relation to the tissue shear properties and they may be in some 
cases complementary [30]. Elastography can be easily used in the evaluation of the 
thyroid gland considering its conveniently superficial location, but it is still not 
widely adopted in practice or included in all the risk-stratification systems [31].
Presently, only one thyroid US elastography guideline has been published—
the “European Federation of Societies for Ultrasound in Medicine and Biology 
(EFSUMB) Guidelines and Recommendations.” Recommendations are in favor of 
using elastography as an extra tool to gray-scale ultrasound and for the follow-up of 
nodules formerly benign in FNAB [32].
2.1 Strain (quasistatic) elastography
Strain elastography (SE) was the first to be used and most implemented 
technique on US systems. Usually, very slight external pressure is applied by the 
operator (or by acoustic radiation force impulse (ARFI)), or more recently, it has 
the sensitivity to detect minimal endogenous physiological motion (vascular beam 
movements and muscle contraction) [28, 30]. The imaging methods are a little 
different for each manufacturer so each equipment will display images with slightly 
different characteristics [33].
SE equipment does not offer direct quantification of stress. Elastograms illus-
trate relative stiffness and are calculated from the signal differences previously and 
after compression, being displayed in parallel with B-mode image (split-screen) or 
overlaid on the conventional B-mode image. Stiffness of the tissue is displayed usu-
ally in a continuous color map from red (soft or no strain) to green (intermediate 
or equal strain) to blue (hard or no strain). There are some systems available on the 
market that use a reverse color scale [34, 35].
A visual colorimetric analysis based on the displayed qualitative map image 
will be made [32]. Two scoring systems have been proposed for the qualitative 
assessment of nodule elasticity: the Asteria and Rago systems. Asteria classifies 
nodules on a scale from 1 (entirely elastic nodule) to 4 (entirely stiff nodule). Rago 
includes the first four Asteria classes with the addition of the fifth score (entirely 
stiff nodule, infiltrating in the posterior shadowing area) [35]. Lesions that appear 
homogenous or with low stiffness are considered benign, while lesions that present 
increased stiffness are considered to have high malignancy risk [28].
SE machines use special software for an objective semiquantitative determina-
tion providing a numeric value: the strain ratio (SR). This method of elasticity 
assessment represents the ratio between strain value in the neighboring thyroid 
parenchyma and the mean nodule strain (parenchyma-to-nodule ratio) or between 
the strain in a neighboring strap muscle and the thyroid nodule (muscle-to-nodule 
ratio) [32]. Probability of cancer grows with a higher strain ratio [35]. A study 
conducted by Aydin et al. in 2014 showed that there are no significant differences 
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between muscle-to-nodule ratio and parenchyma-to-nodule ratio, suggesting that 
the first ratio could be safely used instead of last ratio in evaluating malignancy 
risk when the thyroid parenchyma is abnormal [36]. SR is considered to be more 
accurate than qualitative elasticity assessment. The final value will represent the 
average of three measurements [37].
Widely different cutoff values have been described for the SR (between 1 and 5), 
currently there is no general agreement: ≥ 2 (Se = 97.3%, Sp = 91.7%) [38]; ≥ 2.09 
(Se = 90.6%; Sp = 93%) [39]; ≥ 2.73 (Se = 89.3%; Sp = 73.2%) [40]; and ≥ 3.79 
(Se = 97.8%; Sp = 85.7%) [41]. Most of these studies included only solid nodules.
Elastography imaging to B-mode size ratio (EI/B ratio) has been suggested to 
be useful in evaluation of breast lesions [42].
The area ratio (AR) is a semiquantitative assessment for SE in virtual touch 
equipment that compares the nodule area on virtual touch image and B-mode, cal-
culating the mean of the three most accurate measurements. A malignancy cutoff 
of 1.08 was suggested [43].
Hard area ratio is the ratio between the nodule hard area and the whole 
nodule area. Different cutoff values for malignancy have been proposed: ≥ 0.45 
(Se = 98.2%; Sp =81.2%) [40] and ≥0.6 (Se = 92.9%, Sp = 91.3%). This parameter is 
highly dependent on the examiner and has poor reproducibility [37].
The elasticity contrast index is available on Samsung machines and measures 
the strain oscillation within a nodule and then uses complex calculation to deter-
mine local contrast. In a malignant lesion, there are large differences between low 
and high strain regions, inducing important local contrast [44].
When choosing the place of the ROI, some aspects have to be taken into con-
sideration. It should be as proximal to the transducer as possible, it should cover 
the entire nodule and “as much of the adjacent parenchyma as possible.” Manual 
compression is quantified on most of the machines for better reproducibility: 
optimal compression in Hitachi machines is considered between 3 and 4 and > 50 in 
Siemens machines [32, 37].
There is a huge body of evidence regarding the diagnostic qualities of the SE 
method in defining benign versus malignant lesion.
In a meta-analysis conducted in 2010 by Bojunga et al. that included eight stud-
ies (639 nodules), RTE recognized thyroid malignancy with overall mean Se = 92% 
(88–96 CI) and mean Sp = 90% (85–95 CI). A significant heterogeneity was found 
for specificity of the different studies [45].
Rago et al. conducted a study on 195 nodules, which concluded that RTE elas-
tography had Se = 94.9%, Sp =90.3%, PPV = 71.1%, and NPV = 98.6% in predicting 
malignancy in nodules with indeterminate or nondiagnostic cytology. Worth men-
tioning is the high NPV of high elasticity-score nodules, which strongly predicts 
benignity [46].
Another valuable study from Italy evaluated SE diagnostic accuracy on 498 nod-
ules showing Se = 97% and NPV = 97% when at least one suspicious US parameters 
was also present [47].
A meta-analysis that included 20 studies evaluating SE diagnostic value in 
benign or malignant nodules showed a pooled Se = 85% (95% CI, 79–90%), 
Sp = 80% (95% CI, 73–86%), NPV = 97% (95% CI, 94–98%), and PPV = 40% (95% 
CI, 34–48%) [48].
Some of SE limitations are represented by its subjectivity, operator-dependency, 
and compressibility-dependency [49].
Increased stiffness can be found in benign nodules with coarse calcification or 
fibrosis, leading to false-positive results [45, 50].
When the evaluated lesion is located deeper, an elastogram can be obtained 
if lesion can be visualized in the B-mode image, but it may require application of 
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more stress by the examiner, which could alter the color map for more superficial 
structures. If nodules are too deep, a false-positive stiff image can appear as a result 
of reduced stress transmission [32].
Nodule size is not considered to interfere with SE evaluation accuracy, although 
there are some studies that reported affected performance on nodules larger than 
3 cm or very small lesions. WFUMB guidelines consider nodules larger than 3 cm 
cannot be evaluated correctly because of their deeper parts and lack of healthy 
adjacent tissue. Coalescent nodules can also not be assessed by SE [32, 37, 51].
Carotid pulsations interfere when external pressure is applied, particularly in 
transverse incidence, the incidence being preferred for elastography with internal 
force [32].
The reference surrounding parenchyma in the ROI should have at least 50% 
green color to obtain an accurate strain ration [37].
Other limitations of SE are presence of peripheral rim calcification—increased 
stiffness; large cystic component—SE in nodules with cystic components should 
be assessed only for the solid component; necrosis—can present soft areas; nodules 
under 5 mm—although a low size limit for SE use was not established; and obese 
patients [50, 51].
It is clear that strain elastography accuracy is highly dependent on the examiner’s 
training. The interobserver variability has been evaluated by several studies that 
recently showed excellent agreement between multiple observers [32]. It seems that 
strain ratio is easily learned compared to elasticity score interpretation [52].
Different pathologies of the thyroid nodules can have an impact on SE appear-
ance. Currently, it is known that follicular carcinomas may appear elastic on SE, 
so elastography is not a useful tool for evaluating this type of thyroid malignancy 
(44% false-negative findings). Other particular pathologies that appear soft on 
elastography and may lead to false-negative results are medullary carcinomas and 
metastatic carcinomas [32, 45].
2.2 Shear-wave elastography
Shear waves are defined as transverse elements of particle displacement which 
are very quickly attenuated by the tissue. Shear represents a modification of shape, 
without a modification of volume [35, 53]. Tissue propagation of shear waves is 
much slower in comparison to longitudinal waves. They do not propagate well in 
water, being rapidly attenuated, but they do propagate in elastic media [54].
Shear-wave elastography (SWE) is more operator-independent, and therefore, 
more reproducible [35]. Quantitative and qualitative assessment of tissue elasticity 
can be obtained by measuring the shear wave speed. Several applicable methods are 
available [27].
1D Transient elastography is widely used for estimating liver fibrosis 
(Fibroscan and Echosens). It cannot be performed with a standard transducer on 
regular ultrasound equipment. The probe used by this device incorporates an US 
transducer as well as a vibrating device that exerts an external vibrating “punch” to 
generate shear waves that will propagate through tissues [27].
In monoplane shear-wave elastography (pSWE), ARFI mechanically excites 
the tissue in the region of interest (ROI) using acoustic push pulses which gener-
ate localized tissue displacements in the US axial direction—perpendicular to the 
surface. Shear wave speed measurements can be made up to 8 cm in depth (m/s) 
[14, 30]. This approach is implemented on devices produced by Phillips (ElastPQ ) 
and Siemens (VitualTouch Quantification, VTQ ) [27].
Biplane shear-wave elastography (SWE, 2D SWE, 3D SWE) offers a real-
time display of a color quantitative elastogram overlaid on a B-mode image and 
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assessment of shear wave speed [27]. Supersonic shear wave uses focused ultrasonic 
beams that spread through the whole imaging area, displaying on a color map the 
velocity (m/s) of the shear wave or directly the elasticity (kilopascals) for every 
pixel in the ROI. A series of parameters in the ROI can be measured: maximum 
stiffness, mean stiffness, and standard deviation (SD) [35].
The following 2D-SWE technologies are currently available on US machines 
by: Siemens (Virtual Touch Imaging Quantification, VTIQ ), SuperSonic Imagine 
(SWE), Philips (SWE), Toshiba (Acoustic Structure Quantification), and GE 
Healthcare (2D-SWE) [27].
The largest recent meta-analysis by Zhang et al. included 16 studies that used 
ARFI-generated SWE to evaluate 2436 nodules had mean Se = 0.80 (95% CI, 
0.73–0.87) and Sp = 0.85 (95% CI, 0.80–0.90) in detecting malignancy. Both Se and 
Sp were found significantly heterogeneous in all the included studies [55].
Another meta-analysis (Dong et al.) on 13 retro/prospective studies detected high 
ARFI VTQ efficacy in detecting thyroid cancer, with pooled Se = 86.3% (95% CI, 
78.2–91.7) and Sp = 89.5% (95% CI: 83.3–93.6) [56].
A meta-analysis by Lin et al. included 15 studies that used point-SWE or 2D 
SWE to investigate 1867 nodules. The pooled Se = 84.3% (95% CI, 76.9–89.7%), 
Sp = 88.4% (95% CI, 84.0–91.7%), PPV = 27.7–44.7%, and NPV = 98.1–99.1% [57].
All the mentioned meta-analyses concluded that SWE (pSWE and 2-D SWE) 
are useful in detecting thyroid malignancy as a complementary tool to gray-scale 
US, which is also a stated recommendation of WFUMB 2017 guidelines [32].
Five to ten consecutive measurements are needed in order to obtain a valid 
median result [32].
Cutoff values again range widely and have been reported for shear-wave velocity 
between 2.4 and 4.7 m/s [32].
One study on 476 nodules established an EI cutoff mean value of above 85 kPa 
(Se = 95%) or one maximum value of above 94 kPa [58]. Another study on VTQ of 
ARFI reported a cutoff point for velocity = 2.87 m/s and for SWV ratio = 1.59. The 
study also pointed out this SWE method has highest diagnostic value for nodules 
>20 mm [59].
Other studies reviewed in the WFUMB guidelines showed cutoff values ranging 
from 2.55 to 2.75 m/s [60–63].
Interobserver and intraobserver reproducibility were reported to be high. One 
study conducted by Grazhdani et al. showed high concordance rate (k = 0.75) 
between two observers [64].
For the characterization of the thyroid lesion, a quantitate measurement for the 
mean value or maximum value of an elasticity is used. Similar to SE, an SR can be 
obtained by comparing adjacent normal parenchyma or surrounding muscle [32].
Some of ARFI technique limitations will be briefly presented.
The size of the ROI is fixed (5 × 6 mm or 20 × 20 mm)—small nodules cannot 
be accurately measured. Also for nodules smaller than 20 mm, wave velocity is 
not stable. Composition of nodules: cystic composition or calcifications cannot be 
evaluated—it is impossible to place the ROI inside the nodule. Depth is an impor-
tant limitation for both pSWE and 2D SWE—the ARFI cannot penetrate nodules 
deeper than 4–5 cm; ARFI can measure velocities only up to 9 m/s—harder nodules 
or areas will not be evaluated properly: the value “x.xx m/s” will be shown.  
Nodules that are located on the thyroid isthmus are a challenge due to their interpo-
sition between the stiff trachea and the skin [32, 37].
Again, not all malignant nodules are elastic. Follicular carcinomas are described 
as soft lesions and are difficult to differentiate from benign lesions. A study by 
Samir et al. proposed a cutoff value of 22.3 kPa for distinguishing thyroid follicular 
cancer from benign follicular lesions (Se = 82%; Sp = 88%) [65].
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For accurate results, an experimented examiner should always perform SWE 
evaluation of the thyroid. The pressure applied on the transducer can influence the 
evaluation results [32].
There are also clear recommendations that in the presence of a stiff nodule, the 
FNAB is recommended, regardless the conventional US characteristics.
In the AACE guidelines, a nodule with high stiffness is directly included in the 
intermediate risk group, elevated stiffness being listed as one of the AACE criteria 
for FNAB. There is a grade-B recommendation for nodules that are stiff on elastog-
raphy to be addressed to FNAB [7].
Also, in the presence of indeterminate cytology findings, they suggest that 
elastography to be considered for extra information. Combined elastography and 
B-mode US is presented to be more trustworthy when excluding nodules from 
biopsy evaluation [7].
ATA guidelines acknowledge usefulness of US elastography for noninvasive 
assessment of malignancy risk when accurate evaluation can be made, but it 
can neither recommend its universal adoption, nor its replacement of classic US 
assessment [19].
European Thyroid Association (ETA) guidelines also state that elastography, 
with its high NPV, can be a helpful instrument for thyroid nodule evaluation and it 
may be used together with gray-scale US, but not replace it [10].
2.3 RTE versus SWE elastography
As mentioned in the EFSUMB guidelines and showed in literature data, both SE 
and SWE represent a useful tool in thyroid nodule stratification of malignancy risk, 
complementary to gray-scale evaluation [32].
Different studies have reported a wide range of values for Se and Sp when 
comparing the two-elastographic methods.
A big meta-analysis on 71 studies with a total of 16,624 patients showed that RTE 
is slightly better in differentiating benignancy from malignancy in thyroid lesions, 
with pooled Se = 82.9% for RTE; Se = 78.4% for SWE and Sp = 82.8% for RTE; and 
Sp = 82.4% for SWE [66].
A head-to-head comparison of two elastographic methods was made only in a 
few studies.
In a publication by Liu et al., 49 patients (64 nodules) underwent both SWE and 
RTE evaluation and results were compared to pathology results. For SE, qualitative 
assessment was made using Rago classification (score 4–5 considered as malignancy 
suspicious) and for SWE—min and max mean elasticity were measured, cutoff 
mean value was 38.3 kPa, with Sp = 68.4%; Se = 86.7%; NPV = 86.7%; PPV = 68.4% 
for SWE and Sp = 79%; Se = 84.4%; NPV = 83.3%; PPV = 64.7% for RTE. The 
study established that SWE is a promising method for the evaluation of thyroid 
malignancy risk, with similar value to RTE, its sensitivity being a little lower and its 
specificity a little higher [67].
A 2017 meta-analysis (Hu et al.) is evaluating 22 studies, which simultaneously 
evaluated diagnostic performance for thyroid malignancy using both RTE and 
SWE techniques. The results showed that the pooled Se = 0.79 (95% CI, 0.73–0.84), 
Sp = 0.87 (95% CI, 0.79–0.92) for SWE compared with Se = 0.84 (95% CI, 0.76–0.90), 
Sp = 0.90 (95% CI, 0.85–0.94) for RTE, was significant lower for SWE technique 
(p < 0.05) [49].
Another study evaluated 138 nodules using gray-scale US, ARFI imaging and 
qualitative strain elastography. Combination of ARFI and RTE specificity for detect-
ing malignancy increased by 20% (Sp = 92 vs. 72% for RTE only), but sensitivity 
decreased by 28% (Se = 48 vs. 76% for RTE alone). When ARFI cutoff was adapted 
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for the combined methods (ES 3–4 and ARFI ≥1.11 m/s), sensitivity was unchanged, 
specificity increased by just 3%. Therefore, there was no significant change in 
accuracy of finding malignant nodules when combining the two methods [63].
Although most literature data suggest RTE is slightly more powerful in differen-
tiating thyroid cancer, there is currently no consensus about which method is better 
and both SE and SWE proved to add important value to classic US evaluation in the 
preoperative approach of thyroid nodules.
2.4 Elastography: place in indeterminate cytology results
Nondiagnostic and indeterminate cytology represent the great limitations of 
FNAC and gray-scale US can sometimes be poorly predictive. About half of these 
nodules can avoid surgery by performing a second biopsy [68]. There was one study 
that reported higher prevalence of cancer on repeat FNAB, maybe as a consequence 
of the class of high-risk nodules that underwent second FNAB [69].
For the clearance of this cytological category, there is currently a general pro-
posal to use molecular markers, but there is still no consensus regarding which 
panel should be used [70].
Several molecular markers have been studied in indeterminate FNAB cytology 
findings. The most studied mutations/rearrangements include BRAF, RAS, RET/
PTC, and PAX8/PPARγ. These markers can predict (“rule in”) malignancy with 
very high sensitivity, having a high positive predictive value (PPV) but if they are 
not present, malignancy cannot be “ruled out,” having a low sensitivity and nega-
tive predictive value (NPV) [70, 71].
The most common molecular tests used in this rapidly developing field will be 
shortly presented. The Afirma Gene Expression Classifier (GEC) is a microarray 
test which investigates mRNA expression of 167 genes [72]. This test has been 
reported to have high NPV (up to 95%) in the Bethesda III and IV categories, 
but low PPV (14–57%), which makes it useful only as a “rule-out” test [72, 73]. 
ThyGenX test identifies over 100 mutations associated with thyroid cancer, using 
a next-generation-sequencing (NGS). ThyraMIR is a newer test (used comple-
mentary to the ThyGenX) that analyzes 10 different microRNA molecules that 
are considered to contribute to cell differentiation and proliferation in thyroid 
pathology. Combining ThyGenX and ThyraMIR in nodules with indeterminate 
cytology showed Se = 89%, Sp = 85%, NPV = 94%, and PPV = 74% [72, 74]. 
ThyroSeq v2 includes analysis of a panel of >1000 mutations and RNA alterations, 
with Se = 90%, Sp = 93%, PPV = 83%, and NPV = 96%, suggesting that this test 
may be useful as both “rule-in” and “rule-out” test for Bethesda III and IV cytol-
ogy [72, 75]. It has been suggested that the thyrotropin receptor (TSHR) mRNA 
test can be useful in indeterminate nodules, its expression being helpful for early 
diagnosis of PTC [72, 76, 77].
Currently, there is no individual molecular marker that can certainly rule out 
malignancy in indeterminate nodules and it is still debatable if there is a cost-
effective combination of these markers that can be used [4, 70, 71].
Elastography has been suggested to define more accurately the presurgical 
malignancy risk in this cytological category to help clinician’s decision whether to 
repeat biopsy or follow-up [32].
A study by Rago et al. tried to refine diagnosis in this category of nodules (142 
indeterminate and 53 nondiagnostic). All patients have been examined by gray-
scale US, color Doppler, and qualitative RTE (modified Ueno score). Indeterminate 
cytology score 1—highly elastic nodule—was found strongly predictive of benignity 
(p < 0.0001); combination of scores 2 and 3 showed Se = 96.8%, Sp = 91.8%, and 
NPV = 99.0% for predicting malignancy. In nondiagnostic cases, Sp, Se, and NPV 
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showed poorer Se, Sp, and NPV for all elastography scores. When considering 
both indeterminate and nondiagnostic, the overall Se = 94.9%, Sp = 90.3%, and 
NPV = 91.3% for scores 2 and 3 [46].
In another study, qualitative RTE failed to make a correct distinction between 
benignity and malignancy in thyroid nodules, cancer was found in 50% of nodules 
scored 1 or 2 on elastogram and in 34% of score 3 nodules. Quantitative assessment 
of elasticity was suggested [78].
A comparison between 2D-SWE (VTIQ ) and molecular testing (Afirma GEC) 
was made in a prospective study in nodules with indeterminate FNAC. SWV 
cutoff for malignancy risk was defined at above 3.59 m/s with Se = 83.9% and 
Sp = 79.2%. SWV measurements were made in the stiffest section; authors men-
tion that measurements of a larger area may result in a decreased SWV. The 
GEC-suspicious group had Se = 90.3% and Sp = 74.2% (PPV of only 47.5%, but 
NPV of 96.7%). The study concluded that both SWV and GEC can independently 
predict thyroid cancer with similar diagnostic value and are particularly useful in 
this cytological category [79].
A more complex study compared diagnostic efficiency of SWE, semiquantita-
tive SE (strain index), classic US, CEUS, and BRAF mutation test in indeterminate 
cytology, but the number of evaluated nodules was relatively small. The study 
outcomes confirmed a slightly better efficiency for RTE compared to SWE in distin-
guishing malignancy; strain index was the one parameter that showed significant 
correlation with pathology results. RTE and SWE do not seem interchangeable but 
may be used complementary. Interestingly, when strain index, SWV, and BRAF 
mutation were considered together, Sp was enhanced, but Se was lower compared to 
US findings alone [68].
This cytological category still remains uncertain in diagnosis, and in some cases, 
a strategy that combines advanced ultrasound methods was documented to provide 
higher accuracy in diagnosis than use of a single technique [68]. More studies are 
required concerning this approach.
2.5 Contrast-enhanced ultrasound (CEUS)
The use of contrast agents in ultrasonography has widely expanded in clinical use 
and may play an important role in identifying thyroid cancers by evaluating tumor 
microcirculation. New-generation contrast agents (SonoVue) are administered 
intravenously and contain sulfur hexafluoride microbubbles that stay in the blood 
flow for a while. The examiner focuses the US image on the ROI and a contrast-
enhanced image is displayed, detecting microvascular changes in the lesion that 
classic Doppler cannot display [80].
CEUS has already changed approach in management of liver lesions, signifi-
cantly improving the number of unnecessary biopsy indications [81].
In studies where CEUS was performed on thyroid lesions, malignity was indi-
cated by hypoenhancement and heterogeneity [80]. Hypoenhancement can be 
explained by the absence of blood supply in the central area of the tumor, due to 
thrombus formation, vascular compression, and necrosis. Neovascularization is 
mainly marginal, promoting tumor expansion [82]. Heterogeneity is explained by 
the complex and aberrant composition of cancerous lesions (fibrotic, presence of 
calcifications, and necrosis areas) [80, 82].
Other indicators of malignancy are the time of wash-in and wash-out, but 
results are controversial. Some studies described early wash-in and wash-out in 
malignant lesions [83, 84], while others have shown late-phase enhancement for 
thyroid cancers compared to perinodular tissue [85] or no significant difference in 
the time of enhancement for benign versus malignant nodules [86].
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Adenomas are characterized by homogeneity and peripheral ring enhancement [80].
Two recent meta-analyses on CEUS diagnostic accuracy showed the pooled 
Se = 0.88 (95% CI, 0.85–0.91); pooled Sp = 0.90 (95% CI, 0.88–0.92) [87]; and a 
pooled Se = 0.853, pooled Sp = 0.87 [88].
Some benign nodules showed pattern described for malignant ones and vice 
versa, so an assessment of both elastography and CEUS was combined in some 
articles.
A study by Zhan et al. aimed to evaluate the aid of CEUS in diagnosis of thyroid 
malignancy. First, 200 thyroid nodules were evaluated using ARFI technique. A 
number of 40 nodules that were in the “gray zone” underwent CEUS. ARFI accurately 
diagnosed 82% of the total nodules, while CEUS accuracy was 90% (p < 0.05) [89].
Cantisani et al. compared Q-elastography with CEUS in thyroid cancer 
assessment. Study results showed that both methods outclassed gray-scale US, 
but Q-elastography was more sensitive than CEUS (Se = 95%, Sp = 88% for 
Q-elastography; Se = 79%, Sp = 91% for CEUS) [83].
However, more studies are required for evaluating the true usefulness of this 
relatively new and promising technique in the differentiation of malignant from 
benign thyroid nodules.
3. Conclusions
Given the great number of thyroid lesions and the rising incidence of thyroid 
cancer, a correct preoperative distinction between benignity and malignancy in 
nodular pathology is crucial.
Ultrasound elastography represents the most important advance in US imaging 
since Doppler. It proved to serve as an important tool in selecting candidates for 
surgery. Elastography is a noninvasive, nonirradiating method that can be eas-
ily learned, adds only a few minutes to classic US evaluation, but provides truly 
valuable additional information. Unfortunately, this technique is still quite new 
and not widely used in clinical practice, so its universal adoption cannot be recom-
mended by the guidelines, but there is important evidence of its clinical utility and 
its application in current practice is increasing. As any imaging technique, it holds 
its limitations [90].
This technique cannot replace the classic, gray-scale ultrasound, and should be 
used complementary to it [7, 10, 25].
Due to its high NPV, thyroid nodules that are scored soft on elastography are 
highly likely to be noncancerous and can be followed-up, avoiding FNAB [91]. 
Therefore, elastography reduces the need for FNA by up to 43% of cases compared 
to gray-scale risk stratification [17]. It also identifies stiff nodules that need biopsy 
and can be missed by gray-scale US alone. Even lesions with low-risk features, but 
high stiffness, are recommended for FNAB [91].
In the case of indeterminate cytology, clinical judgment can be a real challenge 
for practitioners. Elastography proved to predict malignancy better than B-mode 
parameters and can be essential in further management decision for nodules in this 
category.
For an accurate result, it is important that the evaluation should be performed 
by an experienced operator.
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